Introduction
============

Pancreatic cancer is one of the most commonly diagnosed aggressive malignancies worldwide, with poor long-term prognosis.[@b1-cmar-10-4439],[@b2-cmar-10-4439] Patients with pancreatic carcinoma are often in the advanced stage and unresectable at the time of diagnosis, due to the difficulties in early diagnosis. Few of treatment options would be feasible for them. The latest report shows that pancreatic adenocarcinoma is the third cause of cancer-induced death worldwide, with a 5-year OS rate of 8%, while the survival is relatively better in the localized cases with the rate of 32%.[@b1-cmar-10-4439] These patients with unresectable tumor lesions located in the celiac axis and the superior mesenteric artery without evidence of distant metastasis are defined as locally advanced pancreatic cancer (LAPC). Patients with LAPC account for \~30% of all the cases of pancreatic carcinoma,[@b3-cmar-10-4439] with a median survival time of less than 10 months.[@b4-cmar-10-4439]

The front-line therapeutic options for LAPC patients are chemotherapy and radiotherapy, by which survival benefit is limited, and complications and adverse events (AEs) are frequent. Although some newer chemotherapy regimens like gemcitabine plus nab-paclitaxel,[@b5-cmar-10-4439] dasatinib plus gemcitabine,[@b6-cmar-10-4439] FOLFOX-6[@b7-cmar-10-4439],[@b8-cmar-10-4439] and FOLFIRINOX[@b9-cmar-10-4439]--[@b11-cmar-10-4439] appear and have shown a substantial survival benefit in patients with LAPC, the long-term prognosis is still poor and the heterogeneity between these studies is significant.[@b12-cmar-10-4439] Therefore, an optimal treatment for LAPC patients should provide survival benefit, alleviate pain, improve quality of life, but not cause severe compactions.

High-intensity focused ultrasound (HIFU) is an emerging noninvasive ablation procedure which can ablate various solid tumors including LAPC. It can focus ultrasound energy on the target lesions and induce tumor coagulation necrosis by thermal effect.[@b13-cmar-10-4439] Several clinical trials of HIFU palliative therapy for pancreatic carcinoma cases have provided promising results.[@b14-cmar-10-4439],[@b15-cmar-10-4439] HIFU monotherapy[@b16-cmar-10-4439]--[@b21-cmar-10-4439] or in combination with systemic chemotherapy[@b22-cmar-10-4439],[@b23-cmar-10-4439] has been proved to be able to relieve pain and might bring an additional survival benefit with rare severe AEs.

However, the efficacy of HIFU treatment remains to be confirmed by more research and clinical practice. This single-center, prospective, case series was performed to assess the clinical benefit and safety of HIFU treatment for LAPC cases.

Patients and methods
====================

Patients
--------

From January 2014 to December 2016, cytologically or pathologically confirmed unresectable LAPC patients were eligible for treatment in our center. The inclusion criteria were as follows: patients with age ≥18 years; patients with adequate hepatic, renal, and bone marrow function (white blood cell ≥3.9×10^9^/L, absolute neutrophil count ≥1.5×10^9L^, platelets ≥100×10^9^/L, hemoglobin ≥10 g/dL, and serum creatinine ≤150 mmol/L); and patients with an Eastern Cooperative Oncology Group performance status (ECOG PS) of 1. In addition, some cases should be excluded including pregnancy, lactation, metabolic disease, prior cerebrovascular event, active second malignancy, and uncontrolled intermittent illness.

Each patient signed a document of informed consent before enrollment. The research obtained the approval of the ethics committee of Huadong Hospital affiliated to Fudan University and was done according to the Declaration of Helsinki.

Procedures
----------

HIFU was performed using HIFUINT-9000 system (Shanghai A&S Sci-Tec Co., Ltd, Shanghai, China), which is a US-guided device.[@b22-cmar-10-4439] Firstly, tumor location, size, and the morphological characteristics are identified by b-mode sonography, CT, or MRI; in the meantime, the influence of tumor on adjacent organs and blood vessels is also evaluated. Next, the detecting head of this system will complete the re-localization of the therapy area. Finally, the ablation energy focus is controlled to move sequentially along the three-dimensional axis until the target lesion is totally covered. The main HIFU parameters of treatment in this study were the following: input power, 5--10 kW/cm^2^; therapy depth, 2--15 cm; practice-focused sphere, 3 × 3 × 8 mm[@b3-cmar-10-4439]; unit transmit time (t1) : intermission time (t2) =1:2; and HIFU times at each lesion, 8--10 times. All of the parameters can be varied depending on the depth of the tumor.

Observation and measurement
---------------------------

The primary outcome of this single-center, prospective cohort study was OS of patients. The secondary end points were 6- and 12-month survival rates, tumor response rate, carbohydrate antigen (CA) 19-9 response rate, VAS, quality of life, and safety. The evaluation of tumors was conducted by a CT or MRI scan before HIFU ablation, and at 1, 3, 6, and 12 months post-HIFU treatment. The response was determined according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1).[@b24-cmar-10-4439] Serum levels of tumor biomarker CA 19-9 were measured before HIFU ablation and within 1 week after HIFU treatment, and CA 19-9 response was defined as \>50% decline from baseline value. VAS pain scores and quality of life scores were also recorded and assessed before HIFU ablation, and at 1, 3, 6, and 12 months post-HIFU treatment. The European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-core 30 (EORTC-QLQ-C30) was adopted to evaluate the quality of life of patients. AEs were recorded, and the severity was graded in accordance with the Common Terminology Criteria for Adverse Events, version 4.[@b25-cmar-10-4439]

Statistical analyses
--------------------

OS analysis of patients was conducted by the Kaplan--Meier method. To obtain more detailed descriptions of the survival, stratified analyses by the characteristics of cases were also performed. Potential clinicopathological factors influencing the OS rates were evaluated by log-rank test (univariate analysis) and then by Cox proportional hazards model (multivariate analysis). All the data analyses were performed by Stata 12.0 software (StataCorp LP, College Station, TX, USA). A *P*-value \<0.05 indicated statistical significance.

Results
=======

Patient baseline characteristics
--------------------------------

In total, 87 patients were enrolled in this study. The cases included 41 males and 36 females, with a median age of 68 years (range: 38--80 years). Median Karnofsky performance status (KPS) was 80; 58 cases had a KPS score ≥80 and 29 cases \<80. The median VAS prior to HIFU was 3 (range: 0--8); 70.1% of the cases had a VAS ≥4. The mean of maximum diameter was estimated to be 3.7 cm (range: 1.7--6.9 cm); 41 cases had a mean diameter ≥3 cm and 46 cases \<3 cm. A majority (91%) of the tumors were located in the head and body of the pancreas. Many patients received other therapies before enrollment, including chemotherapy (26), radiotherapy (6), and surgery (12), however, some of them did not achieve remission, and others had relapsed in the short term. Details of the baseline characteristics of patients and tumors are described in [Table 1](#t1-cmar-10-4439){ref-type="table"}.

OS and 6- and 12-month survival rate and the risk factors of OS
---------------------------------------------------------------

Median OS was estimated to be 12.2 months, with 95% CI of 11.1--12.7 months. The 6-month and 12-month survival was 94.25% (95% CI =86.74--97.57) and 50.85% (95% CI =38.17--62.21), respectively. The risk factors of survival were analyzed with a Cox proportional hazards model, which suggested that cases with VAS \<4, KPS ≥80, and tumor size \<3 cm have a significant improvement in the OS (HR =0.26 \[95% CI =0.12--0.57\], *P*=0.001; HR =0.34 \[95% CI =0.17--0.68\], *P*=0.02; and HR=0.39 \[95% CI =0.20--0.78\], *P*=0.007; respectively) after adjusting for age, VAS, KPS, and tumor size ([Table 2](#t2-cmar-10-4439){ref-type="table"} and [Figure 1](#f1-cmar-10-4439){ref-type="fig"}).

Clinical response and CA 19-9 response
--------------------------------------

Among 87 patients administrated with HIFU ablation, complete response (CR), partial response (PR), stable disease (SD), and progression disease (PD) were observed in 7, 25, 36, and 19 patients, respectively. Objective response rate (ORR, CR+ PR) was found to be 36.8% (32/87). Disease control rate (CR+ PR+ SD) was observed to be 78.2% (68/87) ([Table 3](#t3-cmar-10-4439){ref-type="table"} and [Figure 2](#f2-cmar-10-4439){ref-type="fig"}).

Results obtained for tumor biomarker CA 19-9 are also presented in [Table 3](#t3-cmar-10-4439){ref-type="table"}. Patients achieved a CA 19-9 response at a median of 1 month (0.8--1.6). The mean nadir decrease from baseline was 4,077 U/mL. Nearly one-third of patients receiving HIFU treatment had a decrease exceeding 90% from the baseline level, and more than 50% of patients had a decrease exceeding 50% ([Table 3](#t3-cmar-10-4439){ref-type="table"}).

VAS pain score
--------------

The mean VAS pain assessment score was 4.62 (±SD 2.07) at baseline, and was 3.20 (±SD 1.21), 3.18 (±SD 1.02), 3.36 (±SD 1.24), and 3.79 (±SD 1.36) at 1, 3, 6, and 12 months after HIFU ablation, respectively. As shown in [Figure 3](#f3-cmar-10-4439){ref-type="fig"}, a significant decrease from baseline levels (*P*\<0.05) was observed at 1, 3, and 6 months post-HIFU therapy.

Quality of life
---------------

Function scores, global health scores, and symptom scores were converted into the centesimal system from 0 to 100. A higher score in both function and global health scales post-conversion indicated an increased ability of patients to do daily activities. Meanwhile, high scores of symptom scales indicated suffering of the patients. The results are shown in [Figure 4](#f4-cmar-10-4439){ref-type="fig"}. Global health status, physical function, emotional function, and cognitive function of patients were significantly (*P*\<0.05) improved after HIFU treatment. Symptom scales revealed that fatigue and pain were significantly (*P*\<0.05) reduced after HIFU therapy.

Safety
------

All the reported AEs are listed in [Table 4](#t4-cmar-10-4439){ref-type="table"}. Fatigue (14/87, 16.1%) is the most common AE, followed by abdominal pain (7/87, 8%), fever (7/87, 8%), nausea (5/87, 5.7%), and rash (4/87, 4.6%). Besides, elevated C-reactive protein levels, leucopenia and a subcutaneous nodule were reported by each of the two patients. It is worth mentioning that no patient complained of skin burns in our study. No cases of acute pancreatitis or peritonitis were observed during the follow-up period post-HIFU treatment. Moreover, no case withdrew from this research because of the side effects and no treatment-induced death was observed.

Discussion
==========

Patients with unresectable LAPC are still in dire need of effective therapies, because of the limited efficacy of current therapeutic options. These treatments should improve patients' symptoms, relieve pain, and improve quality of life, rather than just achieving sufficient local tumor control. In this regard, HIFU ablation might be one of the appropriate therapies for patients with LAPC. During HIFU treatment, ultrasonic energy is focused on the target lesions, resulting in coagulative necrosis of lesions by thermal and cavitation effects.[@b26-cmar-10-4439],[@b27-cmar-10-4439] Moreover, HIFU treatment is reported to have the ability to enhance tumor immunity of patients.[@b28-cmar-10-4439]--[@b30-cmar-10-4439]

HIFU ablation is an emerging therapy with encouraging clinical results. As reported by numerous studies, it could be applied in patients with advanced pancreatic carcinoma safely and effectively.[@b19-cmar-10-4439],[@b31-cmar-10-4439],[@b32-cmar-10-4439] In clinical practice, HIFU combined with chemotherapy is preferred, but not HIFU alone. However, in the present study, the patients did not receive chemotherapy. They refused chemotherapy either because of AEs or medical expenses associated with chemotherapy or fear of relapse following chemotherapy. Zhou[@b14-cmar-10-4439] over-viewed 241 articles with a total of 653 cases on the HIFU monotherapy for LAPC and revealed that median OS was 10 months and pooled pain remission rate was 71.3% ([Table 5](#t5-cmar-10-4439){ref-type="table"}). The AEs associated with HIFU treatment were rare and tolerable, especially for patients of older age and with poor ECOG PS. Therefore, HIFU ablation could be considered as an optimal treatment for elderly cases and for those with low ECOG PS, who are unavailable for chemotherapy or radiotherapy.

In our subjects, the median OS was found to be 12.2 months, with 95% CI of 11.1--12.7 months. As a golden standard treatment for LAPC, patients undergoing first-line treatment with gemcitabine were reported to have a median OS of 5.6--9.2 months in numerous high-quality randomized controlled trials.[@b33-cmar-10-4439]--[@b39-cmar-10-4439] HIFU treatment might prolong the survival of patients to a greater extent, when compared with gemcitabine monotherapy. The 6-month and 12-month OS rates of 94.25% and 50.85%, respectively, in this study are comparable to the rates obtained with chemotherapy and radiotherapy in LAPC.[@b23-cmar-10-4439],[@b40-cmar-10-4439] In a study by Zhao et al[@b41-cmar-10-4439] in 2017, the 6-month OS was found to be 44.4%--100% and 12-month OS was 11.1%--35.4% after HIFU treatment, which is numerically inferior to our results. Some factors such as sample size, statistical power, and baseline value might have contributed to this difference.

In terms of the AEs, during and after HIFU therapy, no serious adverse reactions were observed in this study. The treatment-related complication, as well as treatment cycle, was significantly reduced compared with chemotherapy or radiotherapy.[@b42-cmar-10-4439],[@b43-cmar-10-4439] However, recent reports have reported certain HIFU-related complications, especially skin burns, but our results did not show any evidence of complications due to skin burn. This can be attributed to the differences in the type of HIFU equipment used for treatment. HIFUNIT-9000 system used in this study adopts dual focus mode, and the energy upon the skin could be reduced effectively during operation compared with other equipment.

Several limitations of this study should be acknowledged. First, our results came from a single-center, non-blinded observation study, which would not provide the highest quality evidence of clinical practice. Second, our sample scale is relatively small, and the follow-up period is relatively short. Therefore, top-level designed trials with a larger sample size are needed. Nevertheless, our investigation has provided a reliable clinical evidence for the new direction of LAPC ablation treatment.

Conclusion
==========

Our results further confirmed the efficacy and safety of HIFU treatment for patients with LAPC. HIFU might be one of the optimal therapies for LAPC. However, further well-designed double-blind, randomized controlled trials are warranted to evaluate the clinical efficacy of HIFU ablation, especially in combination with chemotherapy or radiotherapy.
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![The Kaplan--Meier survival curve of all the 87 patients.\
**Notes:** (**A**) Overall analysis, (**B**) stratified analysis by VAS, (**C**) stratified analysis by KPS, and (**D**) stratified analysis by tumor size.\
**Abbreviation:** KPS, Karnofsky performance status.](cmar-10-4439Fig1){#f1-cmar-10-4439}

![CT scans of a 63-year-old male patient with LAPC who received HIFU treatment.\
**Notes:** (**A**) Before treatment, pancreatic cancer invaded local blood vessels. An irregular low-density mass with 2.6×3.0 cm could be seen in the head of the pancreas. The boundaries between the lesion and the hepatic artery, superior mesenteric vein, and the proximal end of the splenic vein were unclear, and the pancreatic duct was dilated. (**B**) One year after HIFU treatment, the pancreas atrophied, a small amount of pancreatic tissue was seen on the head of the pancreas, no obvious space-occupying lesions were seen, the gap of peripancreatic fat was clear, and there was no sign of pressure on the surrounding blood vessels.\
**Abbreviations:** HIFU, high-intensity focused ultrasound; LAPC, locally advanced pancreatic cancer.](cmar-10-4439Fig2){#f2-cmar-10-4439}

![The VAS of patients at baseline and 1, 3, 6, and 12 months after HIFU treatment. \*p\<0.05 compared with Baseline.\
**Abbreviation:** HIFU, high-intensity focused ultrasound.](cmar-10-4439Fig3){#f3-cmar-10-4439}

![QOL of patients was evaluated by EORTC QLQ-C30 questionnaire.\
**Notes:** High levels of global health and function scales (**A**) indicated a higher ability, and high scores of symptom-scales (**B**) indicated suffering of the patients. \*p\<0.05 compared with Baseline.\
**Abbreviations:** EORTC QLQ-C30, European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-core 30; ; M, months; QOL, quality of life.](cmar-10-4439Fig4){#f4-cmar-10-4439}

###### 

Patient baseline characteristics

  Characteristics                                                            No of patients (%/range)
  --------------------------------------------------------- ---------------- --------------------------
                                                                             
  Gender                                                    Male             41 (47.1%)
                                                            Female           46 (52.9%)
  Age (years)[a](#tfn1-cmar-10-4439){ref-type="table-fn"}   Median (range)   68 (38--80)
                                                            ≥70              34 (39.1%)
                                                            \<70             53 (60.9%)
  BMI (kg/m^2^)                                             Median (range)   22.6 (16.5--29.3)
                                                            \<18.5           34 (39.1%)
                                                            18.5--24         39 (44.8%)
                                                            \>24             14 (16.1%)
  KPS[a](#tfn1-cmar-10-4439){ref-type="table-fn"}           Median (range)   80 (60--100)
                                                            ≥80              58 (66.7%)
                                                            \<80             29 (33.3%)
  VAS[a](#tfn1-cmar-10-4439){ref-type="table-fn"}           Median (range)   3 (0--8)
                                                            ≥4               61 (70.1%)
                                                            \<4              26 (29.9%)
  Tumor location                                            Head             52 (59.8%)
                                                            Body             29 (33.3%)
                                                            Tail             6 (6.9%)
  Prior treatment                                           Chemotherapy     26 (29.9%)
                                                            Radiotherapy     6 (6.9%)
                                                            Surgery          12 (13.8%)
                                                            None             31 (35.6%)
  Tumor size (cm)                                           Median (range)   3.7 (1.7--6.9)
                                                            ≥3               41 (47.1%)
                                                            \<3              46 (52.9%)
  CA 19-9 (U/mL)                                            Median (range)   3,779 (0--23,790)
                                                            Positive         77 (88.5%)
                                                            Negative         10 (11.5%)

**Notes:**

Data are median (range); n (%).

**Abbreviations:** BMI, body mass index; CA, carbohydrate antigen; KPS, Karnofsky performance status.

###### 

Patients' OS and the risk factor analysis of OS

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristics                  Median OS\          6-month OS\            12-month OS\           Log-rank *P*-value   aHR\                                                   Cox *P*-value
                                   (95% CI)            (95% CI)               (95% CI)                                    (95% CI)[a](#tfn3-cmar-10-4439){ref-type="table-fn"}   
  ----------------- -------------- ------------------- ---------------------- ---------------------- -------------------- ------------------------------------------------------ ---------------
                                                                                                                                                                                 

  Overall                          12.2 (11.1--12.7)   94.25 (86.74--97.57)   50.85 (38.17--62.21)                                                                               

  Gender            Male           12.3 (8.4--13.4)    92.68 (79.00--97.58)   53.52 (35.78--68.38)   0.736                                                                       

                    Female         12.1 (10.8--12.5)   93.48 (81.13--97.85)   46.90 (28.71--63.17)                                                                               

  Age (years)       ≥70            11.1 (8.4--12.3)    88.24 (71.63--95.41)   31.35 (12.70--52.10)   0.0015               1.79 (0.88--3.65)                                      0.107

                    \<70           12.5 (11.3--14.1)   96.23 (85.74--99.04)   60.32 (44.26--73.09)                        1                                                      

  BMI (kg/m^2^)     \<18.5         10.6 (7.6--12.5)    85.29 (68.21--93.60)   36.90 (16.96--57.10)   0.0147                                                                      

                    18.5--24       12.1 (12.1--13.4    100 (100-100)          67.13 (48.50--80.29)                                                                               

                    \>24           11.2 (6.2--16.7)    85.71 (53.94--96.22)   31.75 (5.56--63.41)                                                                                

  Location          Head           11.2 (9.7--12.7)    90.38 (78.43--95.88)   46.82 (30.22--61.80)   0.784                                                                       

                    Body           12.3 (10.8--13.4)   89.66 (71.26--96.54)   45.93 (24.75--64.82)                                                                               

                    Tail           13.0 (12.1--17.6)   100 (100--100)         80.00 (20.38--96.92)                                                                               

  VAS               ≥4             10.7 (8.7--11.6)    90.18 (81.42--96.50)   26.66 (13.78--41.41)   0.0000               3.90 (1.76--8.62)                                      0.001

                    \<4            14.1 (12.6--18.0)   96.15 (75.69--99.45)   82.42 (59.53--90.34)                        1                                                      

  KPS               ≥80            12.6 (11.3--14.1)   96.55 (86.91--99.13)   59.50 (43.02--72.76)   0.0002               0.34 (0.17--0.68)                                      0.02

                    \<80           10.6 (6.5--12.3)    86.12 (67.31--94.59)   33.89 (16.05--52.73)                        1                                                      

  Tumor size (cm)   ≥3             10.4 (7.9--11.6)    92.68 (79.00--97.58)   26.32 (11.35--44.08)   0.0001               2.56 (1.28--5.01)                                      0.007

                    \<3            12.9 (12.3--13.4)   93.48 (81.13--97.85)   68.74 (51.14--81.09)                        1                                                      

  Prior treatment   Chemotherapy   12.1 (7.0--12.4)    96.15 (80.52--99.27)   49.26 (31.19--79.07)   0.069                                                                       

                    Radiotherapy   14.4 (8.4--17.6)    100 (100--100)         66.67 (23.08--88.36)                                                                               

                    Surgery        11.3 (5.9--12.4)    91.30 (76.49--99.47)   53.97 (33.11--70.88)                                                                               

                    None           12.3 (10.4--12.7)   93.61 (79.17--99.46)   51.51 (29.69--69.57)                                                                               
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Note:**

Adjusted by age, VAS, KPS, and tumor size.

**Abbreviations:** aHR, adjusted HR; BMI, body mass index; Karnofsky performance status.

###### 

Maximum RECIST response, CA 19-9 response

  Response                                                                                            No of patients   %/range
  ---------------------------------------------------------------- ---------------------------------- ---------------- ------------------
                                                                                                                       
  RECIST best tumor response                                       Overall response rate (CR + PR)    32               36.8
                                                                                                                       
  CR                                                               7                                  8.0              
  PR                                                               25                                 28.7             
  SD                                                               36                                 41.4             
  DCR (CR + PR+ SD)                                                68                                 78.2             
  CA 19-9 parameters[a](#tfn5-cmar-10-4439){ref-type="table-fn"}   Nadir change, U/mL; Mean (range)   --4,077          --43,065--18,845
                                                                                                                       
  Decrease                                                                                                             
  \>20%                                                            66                                 75.8             
  \>50%                                                            49                                 56.2             
  \>90%                                                            27                                 31.0             
  Time to response, months                                         1                                  0.8--1.6         
                                                                                                                       

**Note:**

Based on patients with baseline assessment above the upper limit of normal and at least one post-baseline CA 19-9 assessment.

**Abbreviations:** CA, carbohydrate antigen; CR, complete response; DCR, disease control rate; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors; SD, stable disease.

###### 

Most frequent AEs (regardless of relationship to HIFU treatment)

  AEs                   No of patients   \%
  --------------------- ---------------- ------
                                         
  Fatigue               14               16.1
  Abdominal pain        7                8.0
  Fever                 7                8.0
  Nausea                5                5.7
  Rash                  4                4.6
  Elevated CRP          2                2.3
  Leucopenia            2                2.3
  Subcutaneous nodule   2                2.3
  Total                 25               28.7

**Abbreviations:** AE, adverse event; CRP, C-reactive protein; HIFU, high-intensity focused ultrasound.

###### 

Summary of recent studies of HIFU monotherapy for advanced pancreatic cancer

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                                                           Pts   Characteristics of pts                               Pain relief (%)   ORR (%)       MST (months)          6-month OS   12-month OS   24-month OS
  ------------------------------------------------------------------------------- ----- ---------------------------------------------------- ----------------- ------------- --------------------- ------------ ------------- -------------
                                                                                                                                                                                                                              

  **Zhao et al 2017**[@b41-cmar-10-4439]                                          38    Unresectable, locally advanced; tumor size unclear   --                --            10.8                  100%         36.40%        --

  **Marinova et al 2018**[@b44-cmar-10-4439]                                      50    Unresectable, advanced; tumor size unclear           84%               --            16.2                  --           --            --

  **Wang et al 2011**[@b18-cmar-10-4439]                                          40    Unresectable, advanced; tumor size 4.3 cm            87.50%            --            8                     58.80%       30.10%        --

  **Sung et al 2011**[@b19-cmar-10-4439]                                          46    Unresectable, advanced; tumor size 4.2 cm            --                77.50%        12.4                  52.20%       30.40%        --

  **Xiong et al 2009**[@b45-cmar-10-4439]                                         89    Unresectable; tumor size unclear                     80%               14.60%        11.2 for stage III\   41.0%\       --            10.3%\
                                                                                                                                                                             5.4 for stage IV      6.5%                       0%

  **Li et al 2012**[@b46-cmar-10-4439]                                            25    Unresectable, advanced; tumor size unclear           92%               --            10                    --           42%           

  **Zhou 2014**[@b14-cmar-10-4439],[a](#tfn8-cmar-10-4439){ref-type="table-fn"}   653   Unresectable, advanced; tumor size unclear           71%               CR: 29.66%\   10.03                 --           --            
                                                                                                                                                               PR: 39.83%                                                     
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Note:**

This article was a review of HIFU for advanced pancreatic cancer.

**Abbreviations:** CR, complete response; HIFU, high-intensity focused ultrasound; MST, median survival time; ORR, objective response rate; PR, partial response; pts, patients HIFU, high-intensity focused.
